

Special Issue

Therapeutic Targets in Chronic Lymphocytic Leukemia

Message from the Guest Editors

In recent years, major progress has been made in understanding the cellular and molecular mechanisms that drive chronic lymphocytic leukemia. This knowledge has resulted in the development of novel drugs that have revolutionized treatment of this disease. Among these, drugs that target the B cell receptor pathway and the antiapoptotic protein BCL2 have already been successfully exploited in the clinic and have become available for routine clinical use. However, although most patients initially respond to treatment with these drugs, the vast majority achieve only a partial remission, and a substantial proportion of these subsequently suffer a relapse or undergo Richter transformation, for which no effective treatment currently exists. To further improve treatment responses, combinations of drugs that target patient-specific genetic lesions and common microenvironmental signals will most likely be required.

Guest Editors

Dr. Luca Laurenti

Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy

Dr. Dimitar Efremov

International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

Deadline for manuscript submissions

closed (31 January 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/57165

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)